Your browser doesn't support javascript.
loading
CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity.
Gressier, Elise; Schulte-Schrepping, Jonas; Petrov, Lev; Brumhard, Sophia; Stubbemann, Paula; Hiller, Anna; Obermayer, Benedikt; Spitzer, Jasper; Kostevc, Tomislav; Whitney, Paul G; Bachem, Annabell; Odainic, Alexandru; van de Sandt, Carolien; Nguyen, Thi H O; Ashhurst, Thomas; Wilson, Kayla; Oates, Clare V L; Gearing, Linden J; Meischel, Tina; Hochheiser, Katharina; Greyer, Marie; Clarke, Michele; Kreutzenbeck, Maike; Gabriel, Sarah S; Kastenmüller, Wolfgang; Kurts, Christian; Londrigan, Sarah L; Kallies, Axel; Kedzierska, Katherine; Hertzog, Paul J; Latz, Eicke; Chen, Yu-Chen E; Radford, Kristen J; Chopin, Michael; Schroeder, Jan; Kurth, Florian; Gebhardt, Thomas; Sander, Leif E; Sawitzki, Birgit; Schultze, Joachim L; Schmidt, Susanne V; Bedoui, Sammy.
Afiliação
  • Gressier E; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia. elise.gressier07@gmail.com.
  • Schulte-Schrepping J; Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany.
  • Petrov L; Systems Medicine, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Bonn, Germany.
  • Brumhard S; Translational Immunology, Berlin Institute of Health (BIH) & Charité University Medicine, Berlin, Germany.
  • Stubbemann P; Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Hiller A; Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Obermayer B; Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Spitzer J; Berlin Institute of Health at Charité, Universitätsmedizin Berlin, Core Unit Bioinformatics, Berlin, Germany.
  • Kostevc T; Institute of Innate Immunity, University of Bonn, Bonn, Germany.
  • Whitney PG; Translational Immunology, Berlin Institute of Health (BIH) & Charité University Medicine, Berlin, Germany.
  • Bachem A; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Odainic A; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • van de Sandt C; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Nguyen THO; Institute of Innate Immunity, University of Bonn, Bonn, Germany.
  • Ashhurst T; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Wilson K; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Oates CVL; Sydney Cytometry Core Research Facility, Charles Perkins Centre, Centenary Institute and University of Sydney, Sydney, New South Wales, Australia.
  • Gearing LJ; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Meischel T; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Hochheiser K; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Greyer M; Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia.
  • Clarke M; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Kreutzenbeck M; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Gabriel SS; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Kastenmüller W; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Kurts C; Institute of Innate Immunity, University of Bonn, Bonn, Germany.
  • Londrigan SL; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Kallies A; Würzburg Institute of Systems Immunology, Max Planck Research Group, Julius-Maximilians-Universität Würzburg, Würzburg, Germany.
  • Kedzierska K; Institute of Experimental Immunology, University of Bonn, Bonn, Germany.
  • Hertzog PJ; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Latz E; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Chen YE; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Radford KJ; Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Chopin M; Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia.
  • Schroeder J; Institute of Innate Immunity, University of Bonn, Bonn, Germany.
  • Kurth F; Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.
  • Gebhardt T; Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia.
  • Sander LE; Department of Biochemistry, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.
  • Sawitzki B; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Schultze JL; Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.
  • Schmidt SV; Department of Microbiology and Immunology at the Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia.
  • Bedoui S; Infectious Diseases and Respiratory Medicine, Charité, Universitätsmedizin Berlin, Berlin, Germany.
Nat Immunol ; 24(6): 979-990, 2023 06.
Article em En | MEDLINE | ID: mdl-37188942
Antiviral CD8+ T cell immunity depends on the integration of various contextual cues, but how antigen-presenting cells (APCs) consolidate these signals for decoding by T cells remains unclear. Here, we describe gradual interferon-α/interferon-ß (IFNα/ß)-induced transcriptional adaptations that endow APCs with the capacity to rapidly activate the transcriptional regulators p65, IRF1 and FOS after CD4+ T cell-mediated CD40 stimulation. While these responses operate through broadly used signaling components, they induce a unique set of co-stimulatory molecules and soluble mediators that cannot be elicited by IFNα/ß or CD40 alone. These responses are critical for the acquisition of antiviral CD8+ T cell effector function, and their activity in APCs from individuals infected with severe acute respiratory syndrome coronavirus 2 correlates with milder disease. These observations uncover a sequential integration process whereby APCs rely on CD4+ T cells to select the innate circuits that guide antiviral CD8+ T cell responses.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article